Infographic | November 13, 2020

Reasons CDMOs Lose Oral Dose Manufacturing Bids

Source: ISR Reports

In Q2, 2019, ISR asked 101 respondents who outsource oral dose drug product manufacturing what is the main reason a CDMO may lose the bid for an outsourced manufacturing project. Regulatory violations / FDA form 483 warnings topped the list, capturing 30% of respondents’ votes. To learn more, follow the link to the Oral Dosage Forms Market Overview and Outlook report preview.

VIEW THE INFOGRAPHIC!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online